Literature DB >> 3827975

Beta 2-glycoprotein-I (apo-H) inhibits the release reaction of human platelets during ADP-induced aggregation.

J Nimpf, H Wurm, G M Kostner.   

Abstract

In order to further characterize the modulation of the ADP-induced aggregation of gel-filtered human platelets by beta 2-glycoprotein-I (beta 2-G-I), the influence of this glycoprotein upon the serotonin (5-HT) release during aggregation was measured. The following results were obtained: beta 2-G-I completely inhibits the 5-HT release during ADP-induced platelet activation. The inhibition is correlated with the inhibition of the second wave of the ADP-induced aggregation. This effect of beta 2-G-I is not dose-dependent and appears above a threshold concentration of 0.1-0.15 mg/ml in the assay. The specificity of the beta 2-G-I interaction with the ADP-activation is supported by results obtained with collagen or thrombin as aggregating agents. In these cases neither the aggregation nor the release is influenced by the glycoprotein. In respect to the results obtained, beta 2-G-I is a potent candidate to be a modulator of ADP-induced platelet activation in vivo.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3827975     DOI: 10.1016/0021-9150(87)90110-9

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  25 in total

1.  Optimising testing for phospholipid antibodies.

Authors:  M Helbert; S Bodger; J Cavenagh; D D'Cruz; J M Thomas; P MacCallum
Journal:  J Clin Pathol       Date:  2001-09       Impact factor: 3.411

Review 2.  Antigenic specificities of "antiphospholipid" autoantibodies.

Authors:  R A Roubey
Journal:  Springer Semin Immunopathol       Date:  1994

3.  Characterization of binding of human beta 2-glycoprotein I to cardiolipin.

Authors:  Z Kertesz; B B Yu; A Steinkasserer; H Haupt; A Benham; R B Sim
Journal:  Biochem J       Date:  1995-08-15       Impact factor: 3.857

4.  Plasmin-cleaved beta-2-glycoprotein 1 is an inhibitor of angiogenesis.

Authors:  Taro Sakai; Krishnakumar Balasubramanian; Sourindra Maiti; Jyotsna B Halder; Alan J Schroit
Journal:  Am J Pathol       Date:  2007-09-14       Impact factor: 4.307

5.  Heterogeneity of the apolipoprotein H*3 allele and its role in affecting the binding of apolipoprotein H (beta 2-glycoprotein I) to anionic phospholipids.

Authors:  M I Kamboh; D R Wagenknecht; J A McIntyre
Journal:  Hum Genet       Date:  1995-04       Impact factor: 4.132

6.  [21-year-old patient with myocardial infarct, transient cerebral ischemia and thrombocytopenia].

Authors:  A Rank; L Lindner; E Hiller
Journal:  Internist (Berl)       Date:  2003-03       Impact factor: 0.743

7.  Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: beta 2-glycoprotein I (apolipoprotein H).

Authors:  H P McNeil; R J Simpson; C N Chesterman; S A Krilis
Journal:  Proc Natl Acad Sci U S A       Date:  1990-06       Impact factor: 11.205

8.  Expression of anticardiolipin cofactor, human beta 2-glycoprotein I, by a recombinant baculovirus/insect cell system.

Authors:  M Igarashi; E Matsuura; Y Igarashi; H Nagae; Y Matsuura; K Ichikawa; T Yasuda; D R Voelker; T Koike
Journal:  Clin Exp Immunol       Date:  1993-07       Impact factor: 4.330

9.  Lupus anticoagulant activity of autoimmune antiphospholipid antibodies is dependent upon beta 2-glycoprotein I.

Authors:  R A Roubey; C W Pratt; J P Buyon; J B Winfield
Journal:  J Clin Invest       Date:  1992-09       Impact factor: 14.808

10.  Beta 2-Glycoprotein I binds factor XI and inhibits its activation by thrombin and factor XIIa: loss of inhibition by clipped beta 2-glycoprotein I.

Authors:  Tong Shi; G Michael Iverson; Jian C Qi; Keith A Cockerill; Matthew D Linnik; Pamela Konecny; Steven A Krilis
Journal:  Proc Natl Acad Sci U S A       Date:  2004-03-08       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.